JAK2-positive latent essential thrombocythemia and splanchnic vein thrombosis: The role of bone marrow biopsy for the diagnosis of myeloproliferative disease

Acta Haematologica

Volumn 121, Issue 4, 2009, Pages 218-220

  Allegra, Alessandro ^a   Alonci, Andrea ^a   Penna, Giuseppa ^a   D'Angelo, Arianna ^a   Rizzotti, Patricia ^a   Granata, Angela ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Essential thrombocythemia; JAK2 mutation; Portal vein thrombosis

Indexed keywords

JANUS KINASE 2; ACENOCOUMAROL; ANTICOAGULANT AGENT; HEPARIN; HYDROXYUREA; JAK2 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; SPLENIC VEIN; SPLENOMEGALY; THROMBOCYTHEMIA; VEIN THROMBOSIS; ABDOMINAL PAIN; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; EPILEPSY; GENETICS; LABORATORY DIAGNOSIS; OVARY POLYCYSTIC DISEASE; PATHOLOGY; PHYSIOLOGY; PORTAL VEIN; THROMBOPHILIA;

ABDOMINAL PAIN; ACENOCOUMAROL; ADULT; ANTICOAGULANTS; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; EPILEPSY; FALSE NEGATIVE REACTIONS; FEMALE; HEPARIN; HUMANS; HYDROXYUREA; JANUS KINASE 2; POLYCYSTIC OVARY SYNDROME; PORTAL VEIN; SPLENIC VEIN; SPLENOMEGALY; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 66149134054     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000221962     Document Type: Article

References (23)

1. Randi ML, Rossi C, Barbone E, Casonato A, Fabris F, Girolami A: Superior sagittal sinus thrombosis in 5 patients with essential thrombocythemia: a possible disease variant. Rev Iberoam Thromb Hemost 1994; 7: 76-78.
2. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
3. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D: Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591. (Pubitemid 30118625)
4. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusomolino E, Pasculto C, Cazzola M, Morra E, Lazzarino M: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-761. (Pubitemid 39482529)
5. Thiele G, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A: European consensus for grading of bone marrow fibrosis and assessment of cellularity in myeloproliferative disorders. Haematologica 2005; 90: 1128-1132.
6. De Stefano V, Teofili L, Leone G, Michiels JJ: Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemostas 1997; 23: 411-418. (Pubitemid 27501780)
7. De Stefano V, Fiorini A, Rossi E, Za T, Chiusolo P, Sica S, Leone G: High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology 2007; 3: 831-832. (Pubitemid 46450639)
8. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM: Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534. (Pubitemid 44953658)
9. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Briere JB: Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553-560. (Pubitemid 40769907)
10. Briere JB: Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 2006; 32: 208-218.
11. Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W: The 2001 World Health Organization (WHO) and updated European clinical and pathological (ECP) criteria for the diagnosis, classification and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 307-340.
12. WHO classification of the chronic myeloproliferative disease (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable; in Jaffe S, Harris NL, Stein H, Vardim JW (eds): WHO Classification of Tumours. Tumours of Haematopoiesis and Lymphoid Tissues. Lyon, IARC, 2001, pp 31-42.
13. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y: JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-861. (Pubitemid 46563588)
14. Patel RK, Lea NC, Heneghan MA: Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038. (Pubitemid 43816970)
15. Colaizzo D, Amitrano L, Tiscia GL: The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61. (Pubitemid 44921067)
16. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HLA, Leebeek FWG: Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91: 1712-1713. (Pubitemid 46032973)
17. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G: Incidence of JAK2 V617F mutation among patients with splanchnic or cerebral vein thrombosis and without chronic myeloproliferative disease. J Thromb Haemost 2007; 5: 708-814. (Pubitemid 46563568)
18. Fiorini A, Chiusuolo P, Rossi E, Za T, Ciminello A, Leone G, De Stefano V: Absence of the JAK2 exon mutations in patients with splanchnic vein thrombosis and without overt myeloproliferative disease. Am J Hematol 2009; 84: 126-127.
19. Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H: JAK2v617f positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86: 793-800. (Pubitemid 47497097)
20. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F: Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91: 169-175. (Pubitemid 43304135)
21. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M: A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007; 1110: 2768-2769. (Pubitemid 47523205)
22. Kiladjian J-J, Cervantes F, Leebek FWG, Marzac C, Cassinat B, Chevret S, Cazals-Haten D, Plesier A, Garcia-Pagan JC, Murad SD, Raffa S, Jansseen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC: The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-4929.
23. Janssen HL, Leebeek FW: JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology 2006; 44: 1391-1393.